LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 201

Suchoptionen

Artikel: Commentary on Composite cognitive and functional measures for early stage Alzheimer's disease trials.

Rentz, Dorene M / Papp, Kathryn V

Alzheimer's & dementia (Amsterdam, Netherlands)

2020 Band 12, Heft 1, Seite(n) e12012

Sprache	Englisch
Erscheinungsdatum	2020-05-15
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2832898-X
ISSN	2352-8729
ISSN	2352-8729
DOI	10.1002/dad2.12012
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Validating Use of Technology for Cognitive Test Assessment.

Rentz, Dorene M

EBioMedicine

2016 Band 11, Seite(n) 23–24

Mesh-Begriff(e)	Biomedical Technology/standards ; Cognition ; Cognition Disorders/diagnosis ; Cognition Disorders/psychology ; Humans ; Psychological Tests/standards ; Reproducibility of Results
Sprache	Englisch
Erscheinungsdatum	2016-09
Erscheinungsland	Netherlands
Dokumenttyp	Letter
ZDB-ID	2851331-9
ISSN	2352-3964
ISSN (online)	2352-3964
DOI	10.1016/j.ebiom.2016.08.002
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 7090: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel: Disease progression and costs at the 3-year follow-up of the GERAS-US study.

Chandler, Julie M / Rentz, Dorene M / Zagar, Anthony / Kim, Yongin / Schwartz, Ronald L / Fillit, Howard

Alzheimer's & dementia (Amsterdam, Netherlands)

2023 Band 15, Heft 2, Seite(n) e12430

Abstract: Introduction: GERAS-US prospectively characterized clinical and economic outcomes of early symptomatic Alzheimer's disease (AD). Societal cost changes were examined in amyloid-positive patients with mild cognitive impairment due to AD (MCI) and mild ... ...

Abstract	Introduction: GERAS-US prospectively characterized clinical and economic outcomes of early symptomatic Alzheimer's disease (AD). Societal cost changes were examined in amyloid-positive patients with mild cognitive impairment due to AD (MCI) and mild dementia due to AD (MILD). Methods: Cognition, function, and caregiver burden were assessed using Mini-Mental State Examination (MMSE), Cognitive Function Index (CFI), and Zarit Burden Interview, respectively. Costs are presented as least square mean for the overall population and for MCI versus MILD using mixed model repeated measures. Results: MMSE score and CFI worsened. Total societal costs (dollars/month) for MCI and MILD, respectively, were higher at baseline ($2430 and $4063) but steady from 6 ($1977 and $3032) to 36 months ($2007 and $3392). Direct non-medical costs rose significantly for MILD. Caregiver burden was higher for MILD versus MCI at 12, 18, and 24 months. Discussion: Function and cognition declined in MILD. Non-medical costs reflect the increasing impact of AD even in its early stages. Highlights: In the GERAS-US study, total societal costs for patients with mild cognitive impairment due to Alzheimer's disease (MCI) and mild dementia due to Alzheimer's disease (MILD) were higher at baseline but steady from 6 to 36 months.Mini-Mental State Examination (MMSE) and Cognitive Function Index (CFI) worsened; the rate of decline was significant for patients with MILD but not for those with MCI.There was a rise in direct non-medical costs at 36 months for patients with MILD.Caregiver burden was higher for MILD versus MCI at 12, 18, and 24 months.Slowing the rate of disease progression in this early symptomatic population may allow patients to maintain their ability to carry out everyday activities longer.
Sprache	Englisch
Erscheinungsdatum	2023-04-19
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2832898-X
ISSN	2352-8729
ISSN	2352-8729
DOI	10.1002/dad2.12430
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates.

Wessels, Alette M / Rentz, Dorene M / Case, Michael / Lauzon, Steve / Sims, John R

Alzheimer's & dementia (New York, N. Y.)

2022 Band 8, Heft 1, Seite(n) e12312

Abstract: Introduction: The Integrated Alzheimer's Disease Rating Scale (iADRS) has been used to detect differences in disease progression in early Alzheimer's disease (AD). The objectives of this study were to enhance understanding of iADRS point changes within ... ...

Abstract	Introduction: The Integrated Alzheimer's Disease Rating Scale (iADRS) has been used to detect differences in disease progression in early Alzheimer's disease (AD). The objectives of this study were to enhance understanding of iADRS point changes within the context of clinical trials, and to establish a minimal clinically important difference (MCID) on the iADRS. Methods: Data from AMARANTH and EXPEDITION3 were analyzed using various approaches, including anchor-based, distribution-based, regression analyses, and cumulative distribution function (CDF) plots. Three potential anchors were examined, including the Clinical Dementia Rating-Sum of Boxes, Mini-Mental State Examination, and Functional Activities Questionnaire. Triangulation of all results was used to determine the MCID for participants with mild cognitive impairment (MCI) due to AD and AD with mild dementia. Results: All three anchors met criteria for "sufficiently associated" (\|r\| = 0.4-0.7). Cumulatively, results from anchor-based and distribution-based results converged to suggest an iADRS MCID of 5 points for MCI due to AD and 9 points for AD with mild dementia. Regression analyses and CDF plots supported these values. Discussion: These findings suggest the iADRS can be used in clinical trials to detect a clinically meaningful outcome of AD progression.
Sprache	Englisch
Erscheinungsdatum	2022-06-06
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2832891-7
ISSN	2352-8737 ; 2352-8737
ISSN (online)	2352-8737
ISSN	2352-8737
DOI	10.1002/trc2.12312
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Increased intraindividual variability in reaction time performance is associated with emerging cognitive decline in cognitively unimpaired adults.

Jutten, Roos J / Amariglio, Rebecca E / Maruff, Paul / Properzi, Michael J / Rentz, Dorene M / Johnson, Keith A / Sperling, Reisa A / Papp, Kathryn V

Neuropsychology

2023 Band 38, Heft 2, Seite(n) 184–197

Abstract: Objective: To investigate whether intraindividual variability (IIV) in reaction time (RT) over monthly administered cognitive tasks is increased in cognitively unimpaired older adults who are at risk for cognitive decline, and whether this is ... ...

Abstract	Objective: To investigate whether intraindividual variability (IIV) in reaction time (RT) over monthly administered cognitive tasks is increased in cognitively unimpaired older adults who are at risk for cognitive decline, and whether this is independent of mean RT performance. Method: N Results: After adjusting for mean RT, increased IIV on complex RT tasks was independently associated with worse EF performance (β = -0.10, 95% CI [-.16, -0.03], Conclusions: Increased variability in monthly RT may reflect subtle EF deficits and provide unique information about short-term cognitive decline in preclinical Alzheimer's disease. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Mesh-Begriff(e)	Humans ; Female ; Aged ; Male ; Cross-Sectional Studies ; Reaction Time ; Alzheimer Disease/psychology ; Amyloid beta-Peptides ; Cognitive Dysfunction/diagnostic imaging ; Cognitive Dysfunction/complications ; Positron-Emission Tomography ; tau Proteins
Chemische Substanzen	Amyloid beta-Peptides ; tau Proteins
Sprache	Englisch
Erscheinungsdatum	2023-11-16
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	1042412-x
ISSN	1931-1559 ; 0894-4105
ISSN (online)	1931-1559
ISSN	0894-4105
DOI	10.1037/neu0000928
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 3002: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel: Computerized cognitive practice effects in relation to amyloid and tau in preclinical Alzheimer's disease: Results from a multi-site cohort.

Young, Christina B / Mormino, Elizabeth C / Poston, Kathleen L / Johnson, Keith A / Rentz, Dorene M / Sperling, Reisa A / Papp, Kathryn V

Alzheimer's & dementia (Amsterdam, Netherlands)

2023 Band 15, Heft 1, Seite(n) e12414

Abstract: Scalable cognitive paradigms that provide metrics such as the Computerized Cognitive Composite (C3) may be sensitive enough to relate to Alzheimer's disease biomarkers in the preclinical clinically unimpaired (CU) stage. We examined CU older adults ( ...

Abstract	Scalable cognitive paradigms that provide metrics such as the Computerized Cognitive Composite (C3) may be sensitive enough to relate to Alzheimer's disease biomarkers in the preclinical clinically unimpaired (CU) stage. We examined CU older adults (
Sprache	Englisch
Erscheinungsdatum	2023-03-20
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2832898-X
ISSN	2352-8729
ISSN	2352-8729
DOI	10.1002/dad2.12414
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: The Mobile Toolbox for monitoring cognitive function.

Gershon, Richard C / Sliwinski, Marti J / Mangravite, Lara / King, Jonathan W / Kaat, Aaron J / Weiner, Michael W / Rentz, Dorene M

The Lancet. Neurology

2023 Band 21, Heft 7, Seite(n) 589–590

Mesh-Begriff(e)	Cognition ; Humans
Sprache	Englisch
Erscheinungsdatum	2023-06-29
Erscheinungsland	England
Dokumenttyp	Letter
ZDB-ID	2081241-3
ISSN	1474-4465 ; 1474-4422
ISSN (online)	1474-4465
ISSN	1474-4422
DOI	10.1016/S1474-4422(22)00225-3
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 5955: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel: Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging.

Rentz, Dorene M / Klinger, Hannah M / Samaroo, Aubryn / Fitzpatrick, Colleen / Schneider, Olivia R / Amagai, Saki / Peipert, John Devin

Alzheimer's & dementia (Amsterdam, Netherlands)

2023 Band 15, Heft 3, Seite(n) e12473

Abstract: The Face Name Associative Memory Exam (FNAME) was introduced into the NIH Toolbox as part of the ARMADA study and establishes normative data for diverse participants, ages 64 to 85+, and proposes cutoff scores between biomarker positive versus negative (+ ...

Abstract	The Face Name Associative Memory Exam (FNAME) was introduced into the NIH Toolbox as part of the ARMADA study and establishes normative data for diverse participants, ages 64 to 85+, and proposes cutoff scores between biomarker positive versus negative (+/-) groups. The FNAME was administered to 257 participants across the clinical spectrum with 122 having amyloid biomarkers. Linear regression explored the association between demographics and FNAME and between amyloid (+/-) groups. Receiver operating characteristic curves (ROC) identified performance thresholds that best discriminated between biomarker (+/-) individuals. Lower FNAME scores occurred in males, older ages, Black/African Americans, Hispanics, and biomarker-positive participants. ROC analyses demonstrated acceptable accuracy (0.73 to 0.77) but only when combined with clinical status. The diagnostic discrimination of amyloid positivity was acceptable but not excellent, suggesting the FNAME may be a better screening indicator of clinical status rather than amyloid deposition in cognitively normal individuals. Normative data are provided.
Sprache	Englisch
Erscheinungsdatum	2023-09-07
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2832898-X
ISSN	2352-8729
ISSN	2352-8729
DOI	10.1002/dad2.12473
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Locus coeruleus integrity and left frontoparietal connectivity provide resilience against attentional decline in preclinical alzheimer's disease.

Pahl, Jennifer / Prokopiou, Prokopis C / Bueichekú, Elisenda / Schultz, Aaron P / Papp, Kathryn V / Farrell, Michelle E / Rentz, Dorene M / Sperling, Reisa A / Johnson, Keith A / Jacobs, Heidi I L

Alzheimer's research & therapy

2024 Band 16, Heft 1, Seite(n) 119

Abstract: Background: Autopsy work reported that neuronal density in the locus coeruleus (LC) provides neural reserve against cognitive decline in dementia. Recent neuroimaging and pharmacological studies reported that left frontoparietal network functional ... ...

Abstract	Background: Autopsy work reported that neuronal density in the locus coeruleus (LC) provides neural reserve against cognitive decline in dementia. Recent neuroimaging and pharmacological studies reported that left frontoparietal network functional connectivity (LFPN-FC) confers resilience against beta-amyloid (Aβ)-related cognitive decline in preclinical sporadic and autosomal dominant Alzheimer's disease (AD), as well as against LC-related cognitive changes. Given that the LFPN and the LC play important roles in attention, and attention deficits have been observed early in the disease process, we examined whether LFPN-FC and LC structural health attenuate attentional decline in the context of AD pathology. Methods: 142 participants from the Harvard Aging Brain Study who underwent resting-state functional MRI, LC structural imaging, PiB(Aβ)-PET, and up to 5 years of cognitive follow-ups were included (mean age = 74.5 ± 9.9 years, 89 women). Cross-sectional robust linear regression associated LC integrity (measured as the average of five continuous voxels with the highest intensities in the structural LC images) or LFPN-FC with Digit Symbol Substitution Test (DSST) performance at baseline. Longitudinal robust mixed effect analyses examined associations between DSST decline and (i) two-way interactions of baseline LC integrity (or LFPN-FC) and PiB or (ii) the three-way interaction of baseline LC integrity, LFPN-FC, and PiB. Baseline age, sex, and years of education were included as covariates. Results: At baseline, lower LFPN-FC, but not LC integrity, was related to worse DSST performance. Longitudinally, lower baseline LC integrity was associated with a faster DSST decline, especially at PiB > 10.38 CL. Lower baseline LFPN-FC was associated with a steeper decline on the DSST but independent of PiB. At elevated PiB levels (> 46 CL), higher baseline LFPN-FC was associated with an attenuated decline on the DSST, despite the presence of lower LC integrity. Conclusions: Our findings demonstrate that the LC can provide resilience against Aβ-related attention decline. However, when Aβ accumulates and the LC's resources may be depleted, the functioning of cortical target regions of the LC, such as the LFPN-FC, can provide additional resilience to sustain attentional performance in preclinical AD. These results provide critical insights into the neural correlates contributing to individual variability at risk versus resilience against Aβ-related cognitive decline.
Mesh-Begriff(e)	Humans ; Female ; Male ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/psychology ; Alzheimer Disease/physiopathology ; Aged ; Locus Coeruleus/diagnostic imaging ; Locus Coeruleus/pathology ; Magnetic Resonance Imaging/methods ; Parietal Lobe/diagnostic imaging ; Aged, 80 and over ; Attention/physiology ; Frontal Lobe/diagnostic imaging ; Frontal Lobe/physiopathology ; Positron-Emission Tomography ; Cross-Sectional Studies ; Neural Pathways/diagnostic imaging ; Neural Pathways/physiopathology ; Cognitive Dysfunction/diagnostic imaging ; Cognitive Dysfunction/physiopathology ; Cognitive Dysfunction/psychology ; Neuropsychological Tests
Sprache	Englisch
Erscheinungsdatum	2024-05-31
Erscheinungsland	England
Dokumenttyp	Journal Article
ZDB-ID	2506521-X
ISSN	1758-9193 ; 1758-9193
ISSN (online)	1758-9193
ISSN	1758-9193
DOI	10.1186/s13195-024-01485-w
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Associations Between Self and Study Partner Report of Cognitive Decline With Regional Tau in a Multicohort Study.

Jadick, Michalina F / Robinson, Talia / Farrell, Michelle E / Klinger, Hannah / Buckley, Rachel F / Marshall, Gad A / Vannini, Patrizia / Rentz, Dorene M / Johnson, Keith A / Sperling, Reisa A / Amariglio, Rebecca E

Neurology

2024 Band 102, Heft 12, Seite(n) e209447

Abstract: Background and objectives: Self-reported cognitive decline is an early behavioral manifestation of Alzheimer disease (AD) at the preclinical stage, often believed to precede concerns reported by a study partner. Previous work shows cross-sectional ... ...

Abstract	Background and objectives: Self-reported cognitive decline is an early behavioral manifestation of Alzheimer disease (AD) at the preclinical stage, often believed to precede concerns reported by a study partner. Previous work shows cross-sectional associations with β-amyloid (Aβ) status and self-reported and study partner-reported cognitive decline, but less is known about their associations with tau deposition, particularly among those with preclinical AD. Methods: This cross-sectional study included participants from the Anti-Amyloid Treatment in Asymptomatic AD/Longitudinal Evaluation of Amyloid Risk and Neurodegeneration studies (N = 444) and the Harvard Aging Brain Study and affiliated studies (N = 231), which resulted in a cognitively unimpaired (CU) sample of individuals with both nonelevated (Aβ-) and elevated Aβ (Aβ+). All participants and study partners completed the Cognitive Function Index (CFI). Two regional tau composites were derived by averaging flortaucipir PET uptake in the medial temporal lobe (MTL) and neocortex (NEO). Global Aβ PET was measured in Centiloids (CLs) with Aβ+ >26 CL. We conducted multiple linear regression analyses to test associations between tau PET and CFI, covarying for amyloid, age, sex, education, and cohort. We also controlled for objective cognitive performance, measured using the Preclinical Alzheimer Cognitive Composite (PACC). Results: Across 675 CU participants (age = 72.3 ± 6.6 years, female = 59%, Aβ+ = 60%), greater tau was associated with greater self-CFI (MTL: β = 0.28 [0.12, 0.44], Discussion: Both self-report and study partner report showed associations with tau in addition to Aβ. Additionally, self-report and study partner report were associated with tau above and beyond performance on a neuropsychological composite. Stratification analyses by Aβ status indicate that associations between self-reported and study partner-reported cognitive concerns with regional tau are driven by those at the preclinical stage of AD, suggesting that both are useful to collect on the early AD continuum.
Mesh-Begriff(e)	Humans ; Female ; Male ; Aged ; tau Proteins/metabolism ; Cognitive Dysfunction/metabolism ; Cognitive Dysfunction/diagnostic imaging ; Cognitive Dysfunction/etiology ; Cross-Sectional Studies ; Positron-Emission Tomography ; Aged, 80 and over ; Amyloid beta-Peptides/metabolism ; Alzheimer Disease/metabolism ; Alzheimer Disease/diagnostic imaging ; Self Report ; Cohort Studies ; Temporal Lobe/metabolism ; Temporal Lobe/diagnostic imaging ; Middle Aged ; Neocortex/metabolism ; Neocortex/diagnostic imaging
Chemische Substanzen	tau Proteins ; Amyloid beta-Peptides
Sprache	Englisch
Erscheinungsdatum	2024-05-29
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	207147-2
ISSN	1526-632X ; 0028-3878
ISSN (online)	1526-632X
ISSN	0028-3878
DOI	10.1212/WNL.0000000000209447
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Ui II Zs.153: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 18: Hefte anzeigen
Zs.MO 374: Hefte anzeigen

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Zum Seitenanfang

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen